Literature DB >> 15387377

Characterization of Lewis lung clonal variants in a model of syngeneic pulmonary murine metastases.

Bill T Storey1, H Keith Pittman, Joseph F Christian, Carl E Haisch, Kathryn M Verbanac.   

Abstract

Lung cancer is the leading cause of cancer-related mortality world-wide. Since the majority of cancer deaths result from metastatic complications, understanding cellular alterations contributing to organ specific metastases is a continuing cancer research goal. Desirable models involve easy, efficient methodologies for development of pulmonary metastases utilizing genetically related syngeneic tumor cell lines varying in clonogenic frequency and growth rate for comparative studies. This work focused on development and characterization of primary and metastatic Lewis lung subclones (LLCC3, LLC1, LLCab) in a histocompatible C57B1/6 model. Surgical resection of primary tumors utilizing these cell lines resulted in reliable development of pulmonary metastases (> 90% of injected mice), while tail-vein injection proved sporadic (20% of injected mice). The preliminary analysis of selected cell-surface molecules indicates potential genetic differences that may underlie phenotypic variations. The combination of subcutaneous resection methodology and variant cell lines results in robust metastatic lung cancer for testing potential therapeutic interventions.

Entities:  

Mesh:

Year:  2004        PMID: 15387377     DOI: 10.1023/b:clin.0000037728.44457.13

Source DB:  PubMed          Journal:  Clin Exp Metastasis        ISSN: 0262-0898            Impact factor:   5.150


  38 in total

Review 1.  CD44 and its partners in metastasis.

Authors:  Serge Jothy
Journal:  Clin Exp Metastasis       Date:  2003       Impact factor: 5.150

Review 2.  Natural killer cells: from no receptors to too many.

Authors:  L L Lanier
Journal:  Immunity       Date:  1997-04       Impact factor: 31.745

3.  Increased rates of pulmonary metastases following sham laparotomy compared to CO2 pneumoperitoneum and the inhibition of metastases utilizing perioperative immunomodulation and a tumor vaccine.

Authors:  P Wildbrett; A Oh; J J Carter; H Schuster; M Bessler; C A Jaboci; R L Whelan
Journal:  Surg Endosc       Date:  2002-05-03       Impact factor: 4.584

Review 4.  Clinical aspects of altered glycosylation of glycoproteins in cancer.

Authors:  T F Orntoft; E M Vestergaard
Journal:  Electrophoresis       Date:  1999-02       Impact factor: 3.535

5.  Taking lessons from dendritic cells: multiple xenogeneic ligands for leukocyte integrins have the potential to stimulate anti-tumor immunity.

Authors:  J Kanwar; R Berg; K Lehnert; G Krissansen
Journal:  Gene Ther       Date:  1999-11       Impact factor: 5.250

6.  Phenotypic characteristics of lewis lung carcinoma cells.

Authors:  G P Gaenko; A M Kozlov; N S Saprykina; E B Dorotnikova; S V Khaidukov; Yu G Molotkovskii
Journal:  Bull Exp Biol Med       Date:  2002-10       Impact factor: 0.804

7.  A disaccharide precursor of sialyl Lewis X inhibits metastatic potential of tumor cells.

Authors:  Mark M Fuster; Jillian R Brown; Lianchun Wang; Jeffrey D Esko
Journal:  Cancer Res       Date:  2003-06-01       Impact factor: 12.701

8.  Vascular endothelial growth factor increased by pulmonary surgery accelerates the growth of micrometastases in metastatic lung cancer.

Authors:  Y Maniwa; M Okada; N Ishii; K Kiyooka
Journal:  Chest       Date:  1998-12       Impact factor: 9.410

9.  Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression.

Authors:  L Holmgren; M S O'Reilly; J Folkman
Journal:  Nat Med       Date:  1995-02       Impact factor: 53.440

10.  Endovascular papillary angioendothelioma (Dabska tumor) of the tongue: report of a case.

Authors:  Kazuki Takaoka; Kazunari Sakurai; Kazuma Noguchi; Susumu Hashitani; Masahiro Urade
Journal:  J Oral Pathol Med       Date:  2003-09       Impact factor: 4.253

View more
  3 in total

1.  TAK1 regulates endothelial cell necroptosis and tumor metastasis.

Authors:  Lida Yang; Sayali Joseph; Tianliang Sun; Julia Hoffmann; Sophia Thevissen; Stefan Offermanns; Boris Strilic
Journal:  Cell Death Differ       Date:  2019-01-25       Impact factor: 15.828

2.  Synthesis and Antitumor Activity of Ellagic Acid Peracetate.

Authors:  Yulin Ren; Min Wei; Patrick C Still; Shunzong Yuan; Youcai Deng; Xiaozhuo Chen; Klaus Himmeldirk; A Douglas Kinghorn; Jianhua Yu
Journal:  ACS Med Chem Lett       Date:  2012-06-17       Impact factor: 4.345

3.  Potentiation of PD-L1 blockade with a potency-matched dual cytokine-antibody fusion protein leads to cancer eradication in BALB/c-derived tumors but not in other mouse strains.

Authors:  Roberto De Luca; Dario Neri
Journal:  Cancer Immunol Immunother       Date:  2018-07-04       Impact factor: 6.968

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.